Agilent Technologies (A) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.25 per share. This compares to earnings of $1.43 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 5.60%. A quarter ago, it was expected that this scientific instrument maker would post earnings of $1.19 per share when it actually produced earnings of $1.22, delivering a surprise of 2.52%. Over the last four ...

Revenue Performance - Revenue for Q3 2024 was $1.58 billion, a decline of 5.6% reported and 4.4% core year-over-year[2] - Full-year revenue outlook revised to $6.450 billion to $6.500 billion, reflecting a decline of 5.6% to 4.9% reported[8] - Fourth-quarter revenue outlook expected between $1.641 billion and $1.691 billion, indicating a decline of 2.8% to an increase of 0.2% reported[8] - Overall GAAP revenue for Agilent decreased by 6% year-over-year, from $1,672 million in Q3'23 to $1,578 million in Q3'24[39] - Agilent's core non-GAAP revenue decreased by 5% year-over-year, from $1,670 million in Q3'23 to $1,578 million in Q3'24[40] Segment Performance - Life Sciences and Applied Markets Group (LSAG) reported Q3 revenue of $782 million, down 8% reported year-over-year[5] - Diagnostics and Genomics Group (DGG) reported Q3 revenue of $385 million, a decrease of 9% reported year-over-year[7] - Agilent CrossLab Group (ACG) reported Q3 revenue of $411 million, an increase of 4% reported year-over-year[6] - Life Sciences and Applied Markets Group revenue decreased by 8% year-over-year, from $854 million in Q3'23 to $782 million in Q3'24[34] - Diagnostics and Genomics Group revenue declined by 9% year-over-year, from $422 million in Q3'23 to $385 million in Q3'24[35] - Agilent CrossLab Group revenue increased by 4% year-over-year, from $396 million in Q3'23 to $411 million in Q3'24[36] - Non-GAAP revenue for Life Sciences and Applied Markets Group showed a constant currency decline of 8% year-over-year[40] - Non-GAAP revenue for Diagnostics and Genomics Group also reflected an 8% decline year-over-year[40] Income and Earnings - GAAP net income was $282 million, with earnings per share (EPS) of $0.97, up 155% from Q3 2023[2] - Non-GAAP net income was $385 million, with EPS of $1.32, down 8% from the same quarter last year[2] - Non-GAAP earnings guidance for fiscal year 2024 revised to a range of $5.21 to $5.25 per share[8] - Net income for the period reached $938 million, a 22.6% increase compared to $765 million for the same period in 2023[23] - The company incurred restructuring and related costs of $67 million during the period, contributing to a diluted EPS impact of $0.23[26] Cash Flow and Assets - Cash flows from operating activities amounted to $1,270 million, slightly up from $1,256 million year-over-year[23] - The company reported a cash balance of $1,782 million at the end of the period, up from $1,332 million a year earlier, marking a 33.6% increase[23] - Total assets increased to $10,996 million as of July 31, 2024, up from $10,763 million on October 31, 2023, representing a growth of 2.16%[22] Liabilities and Equity - Total current liabilities surged to $2,389 million, a significant increase from $1,603 million in the previous period, reflecting a rise of 48.9%[22] - Long-term debt decreased to $2,137 million from $2,735 million, indicating a reduction of 22%[22] - Employee compensation and benefits liabilities decreased to $309 million from $371 million, a decline of 16.7%[22] - The total stockholders' equity increased to $5,903 million from $5,845 million, reflecting a growth of 0.99%[22] Management Insights - The company continues to invest in promising growth opportunities and strategic transformation initiatives to drive margin expansion[1] - Agilent's management emphasizes the importance of non-GAAP measures for evaluating core business performance, which may differ from GAAP results[30] Margins - The gross margin for Life Sciences and Applied Markets Group was 60.2% in Q3'24, slightly up from 60.1% in Q3'23[34] - The operating margin for Diagnostics and Genomics Group decreased to 18.3% in Q3'24 from 22.7% in Q3'23[35]

Agilent Technologies (A) introduced an advanced gas chromatography/mass spectrometry (GC/MS) column technology product namely J&W 5Q GC/MS Columns, in order to expand its Life Sciences and Applied Markets (LSAG) segment.The new GC/MS columns are designed to enhance GC/MS workflows and boost system performance in challenging conditions. With the help of J&W 5Q GC/MS Columns, Agilent strives to meet the demands of modern analytical laboratories. The new columns reduce the frequency of column changes and impro ...

Wall Street analysts expect Agilent Technologies (A) to post quarterly earnings of $1.25 per share in its upcoming report, which indicates a year-over-year decline of 12.6%. Revenues are expected to be $1.56 billion, down 6.6% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company announ ...

Agilent Technologies (A) recently launched its new ProteoAnalyzer system at the Singapore Cell and Gene Therapy Pan Asia Summit.ProteoAnalyzer is an automated parallel capillary electrophoresis solution, enabling rapid, high-resolution protein analysis with minimal sample consumption, facilitating faster discoveries for researchers.This biomolecular platform aims to elevate translational research from compound to novel applications. The platform includes easy-to-use QC workflows for assessing protein size a ...

These are solid stocks that have all generated 10-year returns in excess of 200%.The S&P 500 has remained red hot, achieving gains of nearly 15% through the first six months of 2024. Healthcare stocks have performed well, but not nearly to the same extent -- the Healthcare Select Sector SPDR ETF has risen by 7% during the first half of this year.Healthcare stocks may not generate as much excitement as other growth stocks, but there are some solid options that you can buy and hold, not just for the second pa ...

A month has gone by since the last earnings report for Agilent Technologies (A) . Shares have lost about 0.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Agilent due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Agilent Q2 Earnings Beat EstimatesAgilent Technolo ...

Agilent Technologies (A) is leaving no stone unturned to capitalize on growth opportunities present in the global mass spectrometry (MS) market, which, per a Mordor Intelligence report, is expected to hit $6.77 billion in 2024 and reach $9.17 billion by 2029, witnessing a CAGR of 6.3% between 2024 and 2029.In this regard, the company recently introduced two new products, namely the Agilent 7010D Triple Quadrupole gas chromatography (GC)-MS System and the Agilent ExD Cell.The Agilent 7010D Triple Quadrupole ...

Agilent Technologies, Inc. (NYSE:A) Jefferies 2024 Global Healthcare Conference June 5, 2024 8:30 AM ET Company Participants Robert McMahon - Senior Vice President and Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies Tycho Peterson All right, we're good to go. Good morning, everyone. I'm a Tycho Peterson from the life science team here at Jefferies. Pleased to introduce Bob McMahon from Agilent. Robert McMahon Great, thanks. Thanks, Michael. Good to see you. Great to be here ...

Agilent Technologies, Inc. (NYSE:A) Jefferies 2024 Global Healthcare Conference June 5, 2024 8:30 AM ET Company Participants Robert McMahon - Senior Vice President and Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies Tycho Peterson All right, we're good to go. Good morning, everyone. I'm a Tycho Peterson from the life science team here at Jefferies. Pleased to introduce Bob McMahon from Agilent. Robert McMahon Great, thanks. Thanks, Michael. Good to see you. Great to be here ...